EEI-Biotech Finance interviews Bernard Courtieu

Bernard Courtieu, CEO of IntegraGen, is interviewed by EEI – Biotech for Finance. Mr. Courtieu discusses IntegraGen’s role in the sequencing of liver tumors as a part of a recent publication announcing the identification of a new virus involved in the development of liver cancer. 

The interview (…)  » 

IntegraGen Reports Revenue for First Half of 2015

integragen

IntegraGen today announced its sales for the first half 2015. Sales for IntegraGen’s business totaled € 2.6 million as of June 30, 2015, up 1% compared to the first half of 2014. The company also reported that it experienced a substantial growth in new projects during the first half of 2015 increasing by (…)  » 

IntegraGen presents positive data from two new studies on miR-31-3p biomarker at ASCO 2015

colorectal-cancer-intgragen-biomarker-mir-31-3p

Results from two new studies exploring the role of the microRNA biomarker miR-31-3p in patients with metastatic colorectal cancer were presented during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. The studies reported positive results on the association between miR-31-3p expression and clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with (…)  » 

miR-31-3p oncology biomarker data to be presented at ASCO 2015

Data from two studies reporting results from clinical studies with IntegraGen’s miR-31-3p biomarker is scheduled to be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on May 29 through June 2, 2015.

The first study will report results from research conducted in cooperation (…)  »